Almost 2 decades after linking LRRK2 to Parkinson's disease, a vibrant research field has
developed around the study of this gene and its protein product. Recent studies have begun …

The drug discovery process is a rocky path that is full of challenges, with the result that very
few candidates progress from hit compound to a commercially available product, often due …

Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial
Parkinson's disease and is also linked to its idiopathic form. LRRK2 has been proposed to …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are commonly implicated in the
pathogenesis of both familial and sporadic Parkinson's disease (PD). LRRK2 regulates …

Parkinson's disease predisposing LRRK2 kinase phosphorylates a group of Rab GTPase
proteins including Rab29, within the effector‐binding switch II motif. Previous work indicated …

Since the discovery of leucine-rich repeat kinase 2 (LRRK2) as a protein that is likely central
to the aetiology of Parkinson's disease, a considerable amount of work has gone into …

In the translation of discoveries from the laboratory to the clinic, the track record in
developing disease-modifying therapies in neurodegenerative disease is poor. A carefully …

Autosomal dominant missense mutations that hyperactivate the leucine-rich repeat protein
kinase-2 (LRRK2) are a common cause of inherited Parkinson's disease and therapeutic …

Over the past 20 years, substantial progress has been made in identifying the underlying
genetics of Parkinson's disease (PD). Of the known genes, LRRK2 is a major genetic …

Activating mutations in the leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease,
and previously we showed that activated LRRK2 phosphorylates a subset of Rab GTPases …